论文部分内容阅读
I66新剔除股票从51下降到196名涨升空间大幅下降,盈利动能由正转负是人福医药被剔除出I66的主要原因。近一周内国泰君安将其2011年盈利预测由0.76元调低至0.63元;分析师给出的12个月综合目标价为26.63元,涨升空间为22.89%。三季报业绩符合预期人福医药2011年前三季度实现营业总收入24.31亿元,同比增长65.83%;主营业务利润10.18亿元,同比增长45.73%;营业利润3.54亿元,同比增长35.73%;归属
I66 new excluding stocks fell from 51 to 196 rose sharply decreased space, profitability of positive transfer of negative human welfare medicine was removed from the I66 main reason. In the past week, the domestic Tai Junan lowered its 2011 earnings forecast from 0.76 yuan to 0.63 yuan. The 12-month composite target price given by analysts was 26.63 yuan, up 22.89%. Three quarterly results in line with expectations Humanitarian medicine in the first three quarters of 2011 to achieve total revenue of 2.431 billion yuan, an increase of 65.83%; main business profits of 1.018 billion yuan, up 45.73%; operating profit of 354 million yuan, an increase of 35.73% Belonging